Spectral EMG changes in Cervical Dystonia patients and the influence of botulinum toxin treatment

Journal Article (2017)
Author(s)

SWR Nijmeijer (Universiteit van Amsterdam)

E. de Bruijn (TU Delft - Biomechatronics & Human-Machine Control)

R Verhagen (Universiteit van Amsterdam)

Patrick A. Forbes (TU Delft - Biomechatronics & Human-Machine Control)

DJ Kamphuis (Reinier de Graaf Gasthuis)

R. Happee (TU Delft - Intelligent Vehicles)

MAJ Tijssen (Rijksuniversiteit Groningen)

JHTM Koelman (Universiteit van Amsterdam)

Research Group
Biomechatronics & Human-Machine Control
Copyright
© 2017 S.W.R. Nijmeijer, E. de Bruijn, R. Verhagen, P.A. Forbes, D.J. Kamphuis, R. Happee, M.A.J. Tijssen, J.H.T.M. Koelman
DOI related publication
https://doi.org/10.3390/toxins9090256
More Info
expand_more
Publication Year
2017
Language
English
Copyright
© 2017 S.W.R. Nijmeijer, E. de Bruijn, R. Verhagen, P.A. Forbes, D.J. Kamphuis, R. Happee, M.A.J. Tijssen, J.H.T.M. Koelman
Research Group
Biomechatronics & Human-Machine Control
Issue number
9
Volume number
9
Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Abstract

Botulinum toxin (BoNT) injections in the dystonic muscles is the preferred treatment for Cervical Dystonia (CD), but the proper identification of the dystonic muscles remains a challenge. Previous studies showed decreased 8–14 Hz autospectral power in the electromyography (EMG) of splenius muscles in CD patients. Cumulative distribution functions (CDF’s) of dystonic muscles showed increased CDF10 values, representing increased autospectral powers between 3 and 10 Hz, relative to power between 3 and 32 Hz. In this study, we evaluated both methods and investigated the effects of botulinum toxin. Intramuscular EMG recordings were obtained from the splenius, semispinalis, and sternocleidomastoid muscles during standardized isometric tasks in 4 BoNT-naïve CD patients, 12 BoNT-treated patients, and 8 healthy controls. BoNT-treated patients were measured 4–7 weeks after their last BoNT injections and again after 11–15 weeks. We found significantly decreased 8–14 Hz autospectral power in splenius muscles, but not in the semispinalis and sternocleidomastoid muscles of CD patients when compared to healthy controls. CDF10 analysis was superior in demonstrating subtle autospectral changes, and showed increased CDF10 values in all studied muscles of CD patients. These results did not change significantly after BoNT injections. Further studies are needed to investigate the origin of these autospectral changes in dystonia patients, and to assess their potential in muscle selection for BoNT treatment